You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Vedolizumab for treating moderately to severely active ulcerative colitis

  • Technology appraisal guidance
  • Reference number: TA342
  • Published:  05 June 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination document

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]:  final appraisal determination document Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination document
13 March 2015
(452.44 Kb 11 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 11 March 2015

Back to top